ALMS
Alumis Inc. Common Stock NASDAQ Listed Feb 22, 2021$23.75
Mkt Cap $2.9B
52w Low $2.76
75.4% of range
52w High $30.60
50d MA $25.16
200d MA $13.96
P/E (TTM)
-8.8x
EV/EBITDA
-19.5x
P/B
71.1x
Debt/Equity
0.1x
ROE
-80.8%
P/FCF
-22.4x
RSI (14)
—
ATR (14)
—
Beta
-0.61
50d MA
$25.16
200d MA
$13.96
Avg Volume
1.5M
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
280 East Grand Avenue · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | -0.97 | -0.95 | +2.1% | 25.38 | -2.1% | -1.3% | -8.0% | -9.1% | -2.2% | +3.7% | — |
| Nov 13, 2025 | AMC | -0.92 | -1.06 | -15.2% | 5.28 | -10.0% | +4.5% | +5.7% | +21.4% | +24.4% | +31.1% | — |
| Aug 13, 2025 | AMC | -1.11 | -1.17 | -5.4% | 4.42 | -5.9% | -0.7% | +7.5% | +9.7% | +7.0% | -0.2% | — |
| May 14, 2025 | AMC | -1.47 | -1.82 | -23.8% | 4.51 | -0.4% | +18.6% | +24.6% | +31.9% | +8.2% | +6.0% | — |
| Mar 19, 2025 | AMC | -1.40 | -0.23 | +83.6% | 4.37 | -2.1% | -18.3% | -14.2% | -13.5% | -8.5% | +12.6% | — |
| Nov 13, 2024 | AMC | -1.64 | -1.73 | -5.5% | 10.81 | +1.0% | -13.0% | -18.1% | -20.1% | -4.3% | -10.8% | — |
| Aug 13, 2024 | AMC | -4.50 | -23.10 | -413.3% | 12.54 | -2.3% | +1.4% | +2.6% | +2.1% | +3.7% | +3.7% | — |
| Mar 31, 2024 | AMC | — | -0.96 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | AMC | — | -4.50 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -1.13 | — | — | — | — | — | — | — | — | — |
| Jun 29, 2023 | AMC | — | -0.70 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | AMC | — | -0.69 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30 | Chardan Capital | Maintains | Buy → Buy | — | $24.80 | $24.00 | -3.2% | -18.5% | -11.2% | -8.3% | -5.8% | -11.5% |
| Mar 30 | Oppenheimer | Maintains | Outperform → Outperform | — | $24.80 | $24.00 | -3.2% | -18.5% | -11.2% | -8.3% | -5.8% | -11.5% |
| Mar 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.80 | $24.00 | -3.2% | -18.5% | -11.2% | -8.3% | -5.8% | -11.5% |
| Mar 20 | Chardan Capital | Maintains | Buy → Buy | — | $25.38 | $24.84 | -2.1% | -1.3% | -8.0% | -9.1% | -2.2% | +3.7% |
| Mar 20 | Morgan Stanley | Maintains | Overweight → Overweight | — | $25.38 | $24.84 | -2.1% | -1.3% | -8.0% | -9.1% | -2.2% | +3.7% |
| Jan 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.18 | $18.50 | +1.8% | +7.6% | +16.0% | +21.6% | +33.9% | +32.9% |
| Jan 7 | Guggenheim | Maintains | Buy → Buy | — | $16.23 | $17.39 | +7.1% | +10.4% | +12.0% | +20.5% | +29.9% | +36.2% |
| Jan 7 | Morgan Stanley | Maintains | Overweight → Overweight | — | $16.23 | $17.39 | +7.1% | +10.4% | +12.0% | +20.5% | +29.9% | +36.2% |
| Jan 7 | Leerink Partners | Maintains | Outperform → Outperform | — | $16.23 | $17.39 | +7.1% | +10.4% | +12.0% | +20.5% | +29.9% | +36.2% |
| Jan 6 | Wells Fargo | Maintains | Overweight → Overweight | — | $8.31 | $22.20 | +167.1% | +95.3% | +115.6% | +118.8% | +135.4% | +153.8% |
| Dec 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.58 | $10.59 | +0.1% | +4.5% | +6.7% | +5.7% | +8.2% | +7.8% |
| Aug 15 | Morgan Stanley | Maintains | Overweight → Overweight | — | $4.39 | $4.45 | +1.4% | +8.2% | +10.5% | +7.7% | +0.5% | +4.8% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.42 | $4.16 | -5.9% | -0.7% | +7.5% | +9.7% | +7.0% | -0.2% |
| Jul 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.86 | $4.12 | +6.7% | +0.5% | +4.7% | +2.3% | +6.2% | +7.3% |
| May 15 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.51 | $4.49 | -0.4% | +18.6% | +24.6% | +31.9% | +8.2% | +6.0% |
| Apr 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.33 | $4.23 | -2.3% | -4.4% | -11.5% | +6.0% | +1.6% | +0.5% |
| Apr 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.70 | $4.82 | +2.6% | +5.7% | +0.2% | -8.3% | -8.9% | -12.3% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.00 | $3.82 | -4.5% | +23.0% | +17.5% | +41.0% | +53.5% | +81.0% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.37 | $4.28 | -2.1% | -18.3% | -14.2% | -13.5% | -8.5% | +12.6% |
| Mar 20 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $4.37 | $4.28 | -2.1% | -18.3% | -14.2% | -13.5% | -8.5% | +12.6% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.85 | $4.66 | -3.9% | -1.2% | +3.1% | -5.4% | -5.8% | -10.7% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.88 | $4.70 | -3.7% | -0.6% | -1.8% | +2.5% | -5.9% | -6.4% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.65 | $4.70 | +1.1% | -2.4% | -1.3% | +1.5% | +9.7% | +4.9% |
| Feb 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.59 | $5.33 | -19.1% | -14.0% | -26.9% | -24.0% | -23.7% | -22.6% |
| Jan 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.45 | $8.50 | +0.6% | +4.0% | -4.7% | -9.0% | -17.2% | -14.8% |
| Dec 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.63 | $8.51 | -1.4% | +2.2% | -3.0% | -6.8% | -2.5% | -6.6% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.81 | $10.92 | +1.0% | -13.0% | -18.1% | -20.1% | -4.3% | -10.8% |
No insider trades available.
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
ALMS is adding standard forward-looking statement disclaimers to protect against litigation, suggesting management expects continued uncertainty or competitive pressures ahead.
Mar 30
8-K
Unknown — 8-K Filing
Alumis' Phase 3 validation of envudeucitinib for psoriasis represents a major de-risking event that could drive significant upside if FDA approval proceeds, making this a pivotal inflection point for the stock.
Mar 19
Data updated apr 24, 2026 5:25pm
· Source: massive.com